Development and validation of a risk score (Delay-7) to predict the occurrence of a treatment delay following cycle 1 chemotherapy

BACKGROUND: The risk of toxicity-related dose delays, with cancer treatment, should be included as part of pretreatment education and be considered by clinicians upon prescribing chemotherapy. An objective measure of individual risk could influence clinical decisions, such as escalation of standard...

Descripción completa

Detalles Bibliográficos
Autores principales: Chambers, P., Forster, M.D., Patel, A., Duncan, N., Kipps, E., Wong, I.C.K., Jani, Y., Wei, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024092/
https://www.ncbi.nlm.nih.gov/pubmed/36542904
http://dx.doi.org/10.1016/j.esmoop.2022.100743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024092/
https://www.ncbi.nlm.nih.gov/pubmed/36542904
http://dx.doi.org/10.1016/j.esmoop.2022.100743

Ejemplares similares